Table 1.
Study characteristics of 11 studies
| Author/year of publication | Study design | Treatment line | Treatment | Timing of T assessment | T (ng/dl) median | Cut-off T values | Daily timing | N | F/U median | HR (95% CI) | Univaraiable/multivaraible |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amstrong (2009) [23] | R | 1st | TAX327 | Baseline | 14.5 | Median | NA | 1001 | 20.8 | OS: 0.9(0.76–1.08) | M |
| Bertaglia (2017) [24] | P | 2nd | Abi | Post-DTX | 14.0 | Median | NA | 49 | 23.8 | PFS: 0.79(0.43–1.42) | U |
| de Liano (2014) [25] | R | 1st | Chemotherapy | Baseline | 11.5 | Median | NA | 101 | 20.6 | OS: 0.4 (0.6–1) | M |
| Halabi (2007) [26] | R | 1st | Systematic therapies not specified | Baseline | 18.0 | Continuous variable | NA | 1226 | 33.8 |
OS: 1.01 (1–1.02) PFS: 1 (0.99–1.01) |
M |
| Hashimoto (2019) [8] | R | Mix | Enz/Abi | Before ARTAs (prior DTX 31 pts) | < 5.0 | 5 ng/dl | Morning | 115 | 25.7 | PFS: 0.3 (0.15–1.61) | M |
| Hashimoto (2011) [27] | R | 1st | Bicalutamide/flutamide | Baseline | 10.0 | 5 ng/dl | NA | 30 | 52.5 | PFS: 0.17 (0.05–0.55) | M |
| Lolli (2019) [28] | R | 2nd | Abi | Post-DTX | <2.6 | 2.6 ng/dl | NA | 54 | 35 |
OS: 0.46 (0.23–0.92) PFS: 0.49 (0.26–0.94) |
M |
| 2nd | Enz | 74 |
OS: 0.47 (0.2–1.07) PFS: 0.38 (0.18–0.82) |
M | |||||||
| Montgomery (2015) [29] | R | 2nd | COU-AA 301 | Baseline | NR | 5 ng/dl | NA | 1195 | 20.2 | OS: 0.66 (0.56–0.78) | M |
| Lin (2012) [30] | R | 1st | Ketoconazole | Baseline | 14.0 | 10 ng/dl | NA | 160 | 51.9 | PFS: 0.28 (0.13–0.56) | M |
| Sakamoto (2019) [9] | Mix | Enz/Abi | Baseline | 13.0 | Medain | NA | 107 | 68.3 |
OS: 0.91 (0.3–2.64) PFS: 0.31 (0.1–0.93) |
OS:U, PFS:M | |
| Shiota (2018) [10] | R | Mix | ENZ | Baseline | 3.0 | 5 ng/dl | AM 8–10 | 35 | NR | PFS: 0.72 (0.19–2.13) | M |
| Mix | Abi | 21 | PFS: 2.50 (0.72–8.69) | U | |||||||
| Mix | DTX | 38 | PFS: 2.94 (1.18–7.7) | M |
T testosterone, N number, F/U follow-up, HR hazard ratio, CI confidence interval, R retrospective, P prospective, Abi abiraterone, Enz enzalutamide, DTX docetaxel, ARTAs androgen receptor-targeted agents, NR not reported, OS overall survival, PFS progression-free survival, M multivariable, U univariable